Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.48 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777507 | 0.90 | XDH (0.51) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL1776355 | 0.86 | XDH (0.47) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL4254818 | 0.73 | MPO (0.39) | XDHHSD17B10HPGD | |
| SCHEMBL562980 | 0.72 | XDH (0.67) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL4253369 | 0.72 | XDH (0.51) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL1776468 | 0.70 | XDH (0.49) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL12017486 | 0.70 | XDH (0.55) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL2460104 | 0.69 | XDH (0.43) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL2458365 | 0.68 | XDH (0.47) | XDHGDAKDM4EALDH1A1TSHR | |
| SCHEMBL11036315 | 0.67 | XDH (0.60) | XDHGDAKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2029598-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142576-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | MPO, SERPINB1, XDH | XDH 3/4885GDA 2035/4885KDM4E 4023/4885 |
| US-20080221133-A1 | Compounds | C1R, C1S, AKR1C3 | XDH 1118/4885GDA 4510/4885KDM4E 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.